TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sitting Systolic Blood Pressure (SSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30% reduction in average pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean influenza B-specific serum immunoglobulin (Ig)G titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients achieving immunoprotective titers to influenza B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of abdominal adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in obsessions as rated by visual analogue scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OAB-q scores for severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute myocardial infarction occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Insulin sensitivity (glucose infusion rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative chemotherapy rates by age group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of tachycardia and hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Edinburgh Feeding Evaluation in Dementia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Behavior Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐feeding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐feeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of very low birthweight (<1500 g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma CXCL12 (SDF-1α) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: well-being of older adults
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain score of neck and shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work and life ability, function, feeling and strength of hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: recurrent malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of treatments for malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: average daily total nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT-20 score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complications after procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting total homocysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness and safety of dilatable vs fixed bands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: BICLA response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe flares
Endpoint domain: Adverse events/effects
Primary endpoint: Participation in training
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean training hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reversal of nephrotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vmax value of creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of relapse of leukemia
Endpoint domain: Mortality/survival
Primary endpoint: Children's mean scores for 'pros' subscale on the Decisional Balance Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: macrovascular complication
Endpoint domain: Mortality/survival
Primary endpoint: CFF thresholds reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition, motor and total reaction times impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective sedation ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mRNA expression of inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement on the GAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success
Endpoint domain: Mortality/survival
Primary endpoint: Clinical and radiographic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary treatment failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge from the ED
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contact lens movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLTF thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL center thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMD-related pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief from ulcer pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: survival and microbial response at 42 days
Endpoint domain: Mortality/survival
Primary endpoint: forces required to remove catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total exercise duration (TED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate of thyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Content of serum free thyroxine index (FT4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Content of serum supersensitive thyrotropin (S-TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: smoking prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soft and hard tissue measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of JC‐EUS
Endpoint domain: Adverse events/effects
Primary endpoint: Image quality of JC‐EUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for local staging of esophageal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success rate of IV access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to IV placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COWS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving for opioid drugs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cancer incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: LDL cholesterol lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglyceride lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL cholesterol elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tobacco Smoke Exposure (TSE) elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact on patient care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of S aureus colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of total bacterial colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ACR20 improvement criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour sputum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy of Ovaleap® for stimulation of follicular development
Endpoint domain: Physiological/clinical
Primary endpoint: procedural mortality
Endpoint domain: Mortality/survival
Primary endpoint: Pain score on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference between pre‐operative and intra‐operative point C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total tramadol use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in terbutaline-induced tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attenuation of hypokalaemic effect of terbutaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in terbutaline-induced increases in glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-OH/16α-OHE(1) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opportunistic disease or death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative sore throat severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage to care for HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of pain relief (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of functional relief (PF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient positivity by serotonin release assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heparin/platelet factor 4 enzyme‐linked immunosorbent assay results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Crack cocaine use improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of sex partners
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: ΔALD at the superior level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure-induced kidney dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: KPS score stabilization
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body weight stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total fecal fat excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of left amygdala volume with depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement on the Berg Balance Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the Dynamic Gait Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pupillary diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lower respiratory tract infections (LRTIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in vertigo severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of target behaviours achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete clinical and radiographic healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total kidney volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: non-MI-related target-vessel revascularization (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median sick leave
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recurrence rates of inguinal hernias
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of muscle relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first request for analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Qualitative visibility scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immunological endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body mass index increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sleep score improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: mental development quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of medication-related problems (MRPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful isolation of pulmonary veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician-reported rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of mechanical ventilation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improved joint function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diminished severity of arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diminished severity of synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: restoration success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in S. mutans counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: total dose of morphine in 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean visual analogous scale at several hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients free of rejection at three months
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients experiencing acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients experiencing multiple episodes of rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of FPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of Tg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMI z-score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: under-five mortality
Endpoint domain: Mortality/survival
Primary endpoint: SMA (Self-Management Ability)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean percentage of calories from total fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean percentage of calories from saturated fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean percentage of calories from carbohydrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TH/TP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HP1/(HP2+HP3) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of drug‐free weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue analgesia after codeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma morphine concentration after codeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vomiting after morphine and codeine
Endpoint domain: Adverse events/effects
Primary endpoint: Anxious symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum Creatinine (SCr) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Grade 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Response to treatment at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SKAMP-C score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PERMP scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC exposure of tramiprosate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability and safety of ALZ-801
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive and functional improvements
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Comfort with obesity management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Haemoglobin increase >1 g/dL from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discriminative ability between normal and SKC eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-27 plasma levels as a marker for post-transplant neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sustained efficacy of tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: safety profile of tamsulosin
Endpoint domain: Adverse events/effects
Primary endpoint: long-term tolerability of tamsulosin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cardiac arrest or death from arrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: S-25(OH)D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Colonoscope withdrawal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: perception of benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: level of function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of attempts prior to successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of multi-energy texture analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting serum triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA-insulin resistance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in physical health status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in mental health status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: interproximal plaque removal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admissions related to PNB
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Influenza-specific antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival benefit in patients with diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Relative bioavailability (F) of oral etoposide phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sequential serum E2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ascites grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: persistent parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum levels of MMP-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes